

# Supplementary Materials:

**Table S1.** TNM-based AJCC staging system for ocular adnexal lymphoma, eighth edition

Category	TNM Criteria
<u>Primary tumor (T)</u>	
T0	No evidence of lymphoma
T1	Lymphoma involving the conjunctiva alone without eyelid or orbital involvement
T2	Lymphoma with orbital involvement with or without conjunctival involvement
T3	Lymphoma with preseptal eyelid involvement with or without orbital involvement
T4	Orbital adnexal lymphoma and extraorbital lymphoma extending beyond the orbit to adjacent _____ structure, such as bone, maxillofacial sinuses, and brain
<u>Lymph node involvement (N)</u>	
N0	No evidence of lymph node involvement
N1	Involvement of lymph node region or regions draining the ocular adnexal structures and _____ superior to the mediastinum (preauricular, parotid, submandibular, and cervical nodes)
N1a	Involvement of a single lymph node region superior to the mediastinum
N1b	Involvement of two or more lymph node regions, superior to the mediastinum
N2	Involvement of lymph node regions of mediastinum
N3	Diffuse or disseminated involvement of peripheral and central lymph node regions
<u>Distant metastasis (M)</u>	
M0	No evidence of involvement of other extranodal sites
M1a	Noncontiguous involvement of tissues or organ external to the ocular adnexa (e.g., parotid _____ glands, submandibular gland, lung, liver, spleen, kidney, breast)
M1b	Lymphomatous involvement of the bone marrow
M1c	Both M1a and M1b involvement

**Table S2.** Antibodies used for immunohistochemistry

Antibody	Company	Dilution rate
CD20	DAKO, Santa Clara, CA, US	1:500
CD3	DAKO, Santa Clara, CA, US	1:250
Bcl-2	DAKO, Santa Clara, CA, US	1:300
CD10	LEICA, Buffalo Grove, IL, US	1:50
Cyclin D1	LEICA, Buffalo Grove, IL, US	1:50
Ki-67	DAKO, Santa Clara, CA, US	1:300
IgG	Cell Marque, Darmstadt, Germany	1:300
IgG4	Cell Marque, Darmstadt, Germany	1:1200

**Table S3.** Univariable analysis of prognostic factors

Variable	<u>Response, n (%)</u>		p-value
	CR (n=33)	Non-CR (n=15)	
LDH >225 U/L	13 (39.4%)	10 (76.9%)	0.022*
Ki-67 ≥ 5%	25 (75.8%)	9 (60.0%)	0.266
Treatment (RT or CT with immunotherapy)	26 (78.8%)	7 (46.7%)	0.026*
SUV <sub>max</sub>	2.52 (1.30)	2.64 (1.78)	0.822

\*p < 0.05, Chi-square test and Mann-Whitney test are used. Values are presented with n (%) or mean (standard variation).